Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Liabilities: 2009-2024

Historic Total Liabilities for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to $287.9 million.

  • Madrigal Pharmaceuticals' Total Liabilities rose 148.80% to $736.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $736.7 million, marking a year-over-year increase of 148.80%. This contributed to the annual value of $287.9 million for FY2024, which is 22.38% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Total Liabilities of $287.9 million as of FY2024, which was up 22.38% from $235.2 million recorded in FY2023.
  • Madrigal Pharmaceuticals' Total Liabilities' 5-year high stood at $287.9 million during FY2024, with a 5-year trough of $47.0 million in FY2020.
  • Its 3-year average for Total Liabilities is $229.4 million, with a median of $235.2 million in 2023.
  • Data for Madrigal Pharmaceuticals' Total Liabilities shows a peak YoY spiked of 113.90% (in 2022) over the last 5 years.
  • Madrigal Pharmaceuticals' Total Liabilities (Yearly) stood at $47.0 million in 2020, then surged by 64.22% to $77.2 million in 2021, then soared by 113.90% to $165.2 million in 2022, then surged by 42.40% to $235.2 million in 2023, then grew by 22.38% to $287.9 million in 2024.